Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
47.44%
Operating Margin
9.40%
Net Margin
-420.99%
Efficiency Metrics
Revenue per Expense Ratio
1.10
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
0.00%
Income Tax Rate
25,900,000.0%
EPS
-1.6900000000
Balance Sheet Analysis
Current Ratio
238.16
Cash Ratio
161.11
Working Capital
$303.80M
Debt to Equity
2.70
Debt to Assets
72.12%
Equity Ratio
26.69%
Cash Flow Analysis
Operating Cash Flow Ratio
289.22%
Free Cash Flow Ratio
269.86%
CapEx to Revenue
19.36%
Dividends Paid
$88.42M
Stock Buybacks
No buybacks
Total Shareholder Returns
$88.42M
Cash Position Change
-18.60%
Key Takeaways (2023 FY)
Revenue declined by 82.27170922122%, indicating potential market challenges
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
-82.27%
Net Income
-94.17%
EPS
-116.67%
Operating Income
-100.00%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
25.64%
Operating Cash Flow
-20.27%
Free Cash Flow
-21.66%
Balance Sheet Health
Assets
-24.00%
Debt
-26.95%
Book Value per Share
-15.93%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
-5.93%
Shares Outstanding
1.20%
Long Term Trends
3Y Revenue/Share
198.91%
5Y Revenue/Share
-83.71%
3Y Dividend/Share
-9.93%
5Y Dividend/Share
-30.39%